Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sosei

Roche Basel Switzerland

FDA approval for Roche diagnostic solid tumour test

Test will identify which patients could benefit from GSK immunotherapy.

Roche Basel Switzerland

FDA approval for Roche diagnostic solid tumour test

Test will identify which patients could benefit from GSK immunotherapy.

- PMLiVE

EMA to evaluate Roche arthritis drug RoActemra for severe COVID-19

FDA approval has already been granted following positive phase 3 trials

- PMLiVE

Roche engaged in talks with FDA for Alzheimer’s drug candidate

CEO Severin Schwan told reporters Roche will complete a phase 3 trial of gantenerumab in the second half of 2022

- PMLiVE

Roche’s gantenerumab improves biomarkers in inherited form of Alzheimer’s disease

However, anti-amyloid antibody did not show evidence of cognitive benefit for patients

- PMLiVE

Regeneron’s COVID-19 drug boosts survival in hospitalised patients lacking antibodies

REGEN-COV reduced the risk of death among patients who did not have a natural antibody response

Roche Basel Switzerland

Roche reveals four-year follow-up data for Venclyxto in CLL at EHA2021

At 30 months post-treatment, 26.9% of Venclyxto-treated patients had undetectable minimal residual disease

Roche Basel Switzerland

EC approves Venclyxto-based combinations for newly diagnosed AML

The treatment is approved for newly diagnosed acute myeloid leukaemia patients who can’t receive intensive chemotherapy

Roche Basel Switzerland

Roche’s Tecentriq reduces risk of disease recurrence or death by 34% in some NSCLC patients

Interim results from the phase 3 study to be presented at ASCO 2021

- PMLiVE

Detailed results for Regeneron’s antibody cocktail continue to show benefit in high-risk COVID-19 outpatients

Treatment shortened symptom duration and reduced viral load in non-hospitalised patients with COVID-19

- PMLiVE

Prothena achieves $60m milestone as part of Roche collaboration

Milestone reached as first patient doses in phase 2b trial of prasinezumab in early Parkinson's disease patients

Roche Basel Switzerland

Roche reports strong diagnostics sales in Q1 as demand for COVID-19 tests continues

Company continues to report a significant impact of biosimilar competition on established brands

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links